|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
BEFREE |
We believe that our data will form the basis for future studies of developing GSTO1-1 as a new drug target for cancer therapy.
|
30735370 |
2019 |
|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
BEFREE |
Activity-based protein profiling reveals GSTO1 as the covalent target of piperlongumine and a promising target for combination therapy for cancer.
|
30916079 |
2019 |
|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
BEFREE |
Our study elucidated the role of the GSTO1 inhibitor S2E as a potential therapeutic strategy for preventing chemotherapy-induced breast CSC-mediated cancer metastasis and recurrence.
|
30873742 |
2019 |
|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
BEFREE |
Here we show that silencing of GSTO1 with siRNA significantly impairs cancer cell viability, validating GSTO1 as a potential new target in oncology.
|
27703239 |
2016 |
|
Malignant Neoplasms
|
0.390 |
GeneticVariation
|
group |
BEFREE |
This meta-analysis demonstrates that GSTO2 polymorphism may significantly increase cancer risk in Caucasian population and is associated with elevated risk of breast cancer; while GSTO1 polymorphism is not associated with cancer risk.
|
25300926 |
2014 |
|
Malignant Neoplasms
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Diplotype analysis showed that among subjects exposed to high levels of arsenic, the AGG/AGG variant of GSTO1 Ala140Asp, GSTO2 5'UTR (-183)A/G, and GSTO2 Asn142Asp was associated with an increased cancer risk (HRs, 4.91, 95% CI, 1.02-23.74) when compared to the all-wildtype reference, respectively.
|
21798077 |
2011 |
|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
BEFREE |
P38 and p28 could therefore be relevant as diagnostic markers and/or therapeutic targets in cancer.
|
21359144 |
2011 |
|
Malignant Neoplasms
|
0.390 |
Biomarker
|
group |
CTD_human |
Cancer cells treated with KT53 show heightened sensitivity to the cytotoxic effects of cisplatin, supporting a role for GSTO1 in chemotherapy resistance.
|
21899313 |
2011 |
|
Malignant Neoplasms
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Though polymorphisms have been reported in GSTO1 and GSTO2, their predisposition to cancer risk has not yet been explored.
|
15992993 |
2006 |
|
Malignant Neoplasms
|
0.390 |
GeneticVariation
|
group |
BEFREE |
GSTO polymorphism analysis in thyroid nodules suggest that GSTO1 variants do not influence the risk for malignancy.
|
15901998 |
2005 |
|
Neoplasms
|
0.340 |
AlteredExpression
|
group |
BEFREE |
The increased GSTO1 expression in tumor tissue showed clear correlation with grade and stage.
|
28288548 |
2017 |
|
Neoplasms
|
0.340 |
Biomarker
|
group |
BEFREE |
These potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.
|
27703239 |
2016 |
|
Neoplasms
|
0.340 |
Biomarker
|
group |
CTD_human |
Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance.
|
21899313 |
2011 |
|
Neoplasms
|
0.340 |
GeneticVariation
|
group |
BEFREE |
A higher prevalence of wild-type GSTO1 (A140/A140) was significantly correlated with advanced-stage breast cancer (OR = 0.1, 95% CI, 0.01-0.77), but the presence of the genotype did not correlate with patient age at diagnosis, menopausal status, tumor size, lymph node metastasis, or estrogen-receptor status.
|
20210239 |
2010 |
|
Neoplasms
|
0.340 |
AlteredExpression
|
group |
BEFREE |
No or rare p28 expression was detected in normal or tumour B cells.
|
16639698 |
2006 |
|
Neurodegenerative Disorders
|
0.330 |
GeneticVariation
|
group |
BEFREE |
Two coding single nucleotide polymorphisms (SNPs) supposedly affect their functions: GSTO1*C419A (rs4925) causing alanine to aspartate substitution (*A140D) and GSTO2*A424G (rs156697) causing asparagine to aspartate substitution (*N142D), and have been associated with several neurodegenerative diseases and cancers.
|
30224590 |
2018 |
|
Neurodegenerative Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
Recently, our genetic and molecular studies using the <i>Drosophila</i> system have suggested that GstO1 has a protective function against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity by regulating the MAPK signaling pathway, and GstO2 is required for the activation of mitochondrial ATP synthase in the <i>Drosophila</i> neurodegenerative disease model.
|
29435097 |
2017 |
|
Neurodegenerative Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
Glutathione S-transferase omega 1 and 2 (GSTO1 and 2) protect from oxidative stress, a possible pathogenic mechanism underlying the pathogenesis of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
|
18427999 |
2008 |
|
Neurodegenerative Disorders
|
0.330 |
Biomarker
|
group |
CTD_human |
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.
|
15964507 |
2005 |
|
Lung diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
The polymorphism A140D of GSTO1-1 has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and lung disease in non-exposed populations, suggesting that GSTO1-1 involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.
|
22293942 |
2012 |
|
Lung diseases
|
0.310 |
GeneticVariation
|
group |
BEFREE |
The polymorphism A140D of GSTO1-1 has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and lung disease in non-exposed populations, suggesting that GSTO1-1 involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.
|
22293942 |
2012 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |